Cartalax

Cartalax (Ala-Glu-Asp, AED) is a synthetic tripeptide bioregulator developed by Professor Vladimir Khavinson's research team, derived from kidney and cartilage tissue extracts. It represents the connective tissue-targeted component of the Khavinson bioregulator system, with research interest primarily in cartilage maintenance, fibroblast biology, and kidney tissue support.

The cellular biology of fibroblasts is central to Cartalax research. Fibroblasts are the primary producers of extracellular matrix (ECM) proteins - including collagen types I, III, and IV, fibronectin, and hyaluronic acid - that give connective tissues their structural integrity. As fibroblasts age in culture (a well-established model for cellular aging), their proliferative capacity declines, their collagen production falls, and they transition toward a senescent phenotype characterised by inflammatory cytokine secretion and impaired ECM maintenance. These in vitro changes parallel the in vivo aging of connective tissues, including cartilage.

Research on Cartalax in fibroblast aging models has demonstrated several potentially anti-aging effects. Most notably, Cartalax treatment was associated with maintained expression of Ki-67 - a nuclear protein present in all proliferating cells and absent in quiescent or senescent cells. Ki-67 expression is routinely used as a marker of cellular proliferative activity; its maintenance in Cartalax-treated fibroblasts suggests that the peptide delays the proliferative decline associated with cellular aging.

The modulation of CD98hc expression by Cartalax adds another mechanistic dimension. CD98hc (the heavy chain of the CD98 heterodimer, SLC3A2) is a multifunctional membrane protein involved in amino acid transport, integrin signalling, and cellular resistance to oxidative stress. Its expression level influences cellular fitness and stress resistance - functions that decline with aging. By modulating CD98hc, Cartalax may support multiple aspects of cellular resilience simultaneously.

The cartilage application of Cartalax is particularly relevant given the limited regenerative capacity of cartilage tissue. Unlike most tissues, cartilage is avascular and relies entirely on chondrocytes (which are derived from fibroblastic precursors) for its maintenance. Age-related chondrocyte decline leads to the progressive cartilage loss that characterises osteoarthritis. Research into Cartalax as a potential support for chondrocyte biology and cartilage ECM maintenance represents an important application area.